...
首页> 外文期刊>Biomedicine & pharmacotherapy =: Biomedecine & pharmacotherapie >Immunomodulatory activity of polysaccharide from Helicteres angustifolia L. on 4T1 tumor-bearing mice
【24h】

Immunomodulatory activity of polysaccharide from Helicteres angustifolia L. on 4T1 tumor-bearing mice

机译:来自Helicteres Angustifolia L.在4T1肿瘤的小鼠中的免疫调节活性

获取原文
获取原文并翻译 | 示例
           

摘要

To evaluate the in vivo immunomodulatory activity of the crude polysaccharide from Helicteres angustifolia L. (HACP), a 4T1 breast tumor model in BALB/c mice was used in this study. After tumor incubation for 6 days, mice were orally administered with 100, 200, and 300 mg/kg of HACP for 15 days. The results show that HACP administration resulted in a remarkable immunomodulatory effect attributable to the increased spleen and thymus indices, unregulated CD4(+)/CD8(+) ratios in spleen lymphocytes, and the augmentation of IL-1 beta, IFN-gamma, and TNF-alpha productions in the serum of tumor-bearing mice. The increased immunity resulted in a significant reduction in the tumor weight in 100, 200, and 300 mg/kg of HACP treatment groups, achieving inhibition rates of 34.58 +/- 10.20%, 57.80 +/- 8.65% and 67.71 +/- 5.80%, respectively. In addition, a reduced lung metastasis was also detected in the HACP treatment groups. These findings, for the first time, provide scientific evidence that HACP can improve the immune response in 4T1 tumor-bearing mice, which plays a major role in the antitumor effect. Thus, HACP is prospectively valuable to be developed as new products with immunomodulatory activity and used for the treatment of breast cancer.
机译:为了评价来自Helicteres angustifolia L.(HACP)的粗多糖的体内免疫调节活性,在本研究中使用了Balb / C小鼠的4T1乳腺肿瘤模型。肿瘤孵育6天后,口服小鼠100,200和300mg / kg HACP施用15天。结果表明,HACP给药导致脾脏和胸腺索引增加的显着免疫调节作用,脾脏淋巴细胞中的未调节的CD4(+)/ CD8(+)比,以及IL-1β,IFN-GAMMA的增强TNF-α-血清血清血清的制作。增加的免疫力导致肿瘤重量的显着降低100,200和300mg / kg HACP治疗组,实现抑制率为34.58 +/- 10.20%,57.80 +/- 8.65%和67.71 +/- 5.80 %, 分别。此外,在HACP治疗组中也检测到降低的肺转移。这些发现首次提供科学证据,即HACP可以改善4T1肿瘤患者的免疫应答,这在抗肿瘤效应中起着重要作用。因此,HACP正常有价值的是作为具有免疫调节活动的新产品,用于治疗乳腺癌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号